CRPC w/ Bone Metastases VL

Whole Body MRI Scanning and Disease Progression - Anwar Padhani

Details
Professor Anwar Padhani discusses the value of whole body MRI scanning in diagnosing disease progression at the Radiological Society of North America (RSNA) 2017 conference. Dr. Padhani discusses the biggest advantage of using whole body MRI scanning versus bone or CT scans, which is the ability to detect metastatic disease in bone. Whole body MRI scans are also accurate in detecting castrate-resi...

The Future of Targeted Alpha Therapy - Neal Shore

Details
(Length of lecture - 30 minutes) Dr. Neal Shore discusses the evolving interest in Alpha-Emitting Radionuclide Therapy over the past 20 years, which is due to advances in the targeted delivery of radionuclides as well as increased availability of many different alpha emitters. These developments have led to a number of clinical trials in this space, particularly with Radium-223 , which is the only...

RADAR II Group Recommendations - The Role of Therapeutic Layering

Details
David Crawford, MD discusses with Thomas Keane, MD, the paper, RADAR II: The Role of Therapeutic Layering in Optimizing Treatment for Patients with Castration-Resistant Prostate Cancer, which was designed to offer recommendations on identification of disease progression, treatment management strategies, and suggestions on timing of initiating and discontinuing specific castration-resistant prostat...

Using Fluciclovine in the Recurrent Prostate Cancer Patient- David Schuster

Details
Presentation from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. (Length of lecture 57 minutes) In this lecture, David Schuster describes the mechanisms of uptake of the PET radiotracer fluciclovine and identifies normal biodistribution of fluciclovine. In addition, Dr. Schuster discusses the FDA approval and clinical indication of fluciclovine and the clinical inter...

Radium-223: From Bench to Bed-side, and the Future Directions for Targeted Alpha Therapy - Joe O'Sullivan

Details
Read the complete conference coverage of: 10th International Symposium on Targeted Alpha Therapy, TAT-10 Commentary on the presentation: TAT-10 Special Lunchtime Seminar: Radium 223 from Bench to Bedside, and Future Directions for Targeted Alpha Therapy Radium-223:The Only Approved Targeted Alpha Therapy (TAT) in mCRPC- Outcomes, Opportunities and Lessons Learned : EVERYDAY UROLOGY- Full Text Arti...

Therapeutic Layering in Optimizing Treatment for Patients With CPRC (RADAR II)- Phillip Koo

Details
E. David Crawford interviews Phillip Koo on the RADAR II paper and the key take-aways from the perspective of a nuclear medicine physician treating mCRPC. Biographies: Phillip Koo, MD E. David Crawford, MD

Use of Radium-223 in Clinical Practice: a Radiation Oncologist's Experience - Daniel Spratt

Details
Dr. Daniel Spratt begins his video lecture with an overview of Radium-223 and highlights from the ALSYMPCA trial and improvement of overall survival. Dr. Spratt discusses the current use of Radium-223 and how applicable ALSYMPCA’s results are for today’s patient. The lecture concludes with a look at how to optimize the use of the use of Radium-223. Importantly, by giving Radium-223 as 3 rd or 4 th...

Operationalization of Radium-223 Therapy for Bone Metastases - Eric Rohren

Details
An excerpt from Dr. Eric Rohren's state of the art presentation on Radium-223. This discussion includes the operationalization of Radium-223 at MD Anderson. In addition, a review of different agents available for imaging skeletal metastases with metastatic castration-resistant prostate cancer and a look at patient prognosis and survival data. Biography: Eric Rohren, MD. PhD., a national leader in...

Abiraterone Acetate and Radium-223 in Castrate-Resistant Prostate Cancer: Finding the Right Treatment at the Right Time - Charles Ryan

Details
Chuck Ryan's presentation on Abriaterone Acetate and Radium-223 and finding the right treatment at the right time for the right patient. This discussion is lead by reviewing a patient case study and the practical considerations in the use of novel hormonal agents in the post-ADT setting. Dr. Ryan provides take home points for proactive metastatic castration-restistant prostate thearpy and benefits...

Cristina Nanni on Flucicovine F18 (FACBC) in Prostate Cancer - State of the Art Presentation

Details
Cristina Nanni, MD. a leader in prostate cancer nuclear imaging, presents the data on Flucicovine F18 (FACBC), a new radiopharmaceutical and its application in diagnosisng biochemical replapse in post prostatectomy patients based upon a rising PSA. Dr. Nanni also presents details on its mechanism of action in prostate cancer cells, the current clinical approach and reviews of patient case studies...